Pulse Biosciences Achieves Key Milestones and Reports Q3 Results
Pulse Biosciences, Inc. (NASDAQ: PLSE) recently provided an update on its business progress along with its financial results for the third quarter. The company has made strides in enhancing its innovative Nanosecond Pulsed Field Ablation™ (nsPFA or nano-PFA) technology, revealing exciting developments that position it for future growth.
Business Highlights
Advancements in Soft Tissue Ablation
The company has successfully placed nsPFA Percutaneous Electrode Systems in seven locations across the U.S. This pilot program aims to evaluate clinical effectiveness, with commercial deployment anticipated in the upcoming quarters. Furthermore, Pulse Biosciences is on track to begin a pivotal clinical trial mid-next year to obtain a specific indication for the use of its system in treating benign thyroid nodules.
Innovations in Surgical Atrial Fibrillation (AF) Ablation
In a multi-center, first-in-human feasibility study taking place in Europe, Pulse Biosciences has treated nine patients and is now preparing to submit an Investigational Device Exemption (IDE) to initiate a larger pivotal trial. This step is essential for their plans to secure FDA approval for the nano-PFA Cardiac Surgical System aimed at addressing atrial fibrillation.
Ehancement of Endocardial Catheter AF Ablation
The company is progressing with over 50 patients treated using the nano-PFA 360° Cardiac Catheter. In addition, two new clinical study sites in Europe have been activated for the feasibility study focusing on atrial fibrillation. The team is further bolstered by the appointment of Dr. David Kenigsberg as Chief Medical Officer for Electrophysiology, and Dr. Andrea Natale has joined their electrophysiology medical advisory board.
Third Quarter 2024 Financial Summary
During the third quarter of 2024, Pulse Biosciences incurred total GAAP costs and expenses of $13.7 million, which represents an increase from $11.3 million during the previous year. Factors behind this uptick include increased stock-based compensation and other administrative costs, reflecting the company's efforts to advance its technology and infrastructure. Non-GAAP costs for the quarter amounted to $10.4 million, rising from $9.2 million year-over-year.
The GAAP net loss was reported at ($12.7) million for this quarter, compared to ($10.6) million for the same quarter last year. The company's non-GAAP net loss was ($9.4) million, which was slightly higher than the $8.5 million reported in the previous year.
As of September 30, 2024, Pulse Biosciences' cash and cash equivalents totaled $79.0 million, which includes $60 million raised from a rights offering completed in mid-2024. This financial cushion provides the company with potential for raising an additional $66 million through associated warrant activities. These warrants can be exercised at $11 per share, reflecting the company’s commitment to future growth and expansion.
Preparing for Future Growth
In the third quarter, the purse of cash expenditures remained prudent, with cash used amounting to $8.5 million. This is a strategic move, considering that $8.7 million was used in both the second quarter and the same period a year earlier. The management team's focus remains on maintaining a sound financial strategy while propelling clinical and regulatory initiatives forward.
Webcast and Conference Call
Pulse Biosciences management hosted a conference call to provide additional insights and discuss results in detail. The company's commitment to transparency and communication with stakeholders was apparent in this interaction, highlighting plans for future endeavors and the anticipated impact of their technology on patient care.
About Pulse Biosciences
Pulse Biosciences is at the forefront of bioelectric medicine, dedicated to creating innovative health solutions that significantly enhance the quality of life for patients. Their proprietary CellFX® nsPFA™ technology showcases their strength in delivering electric energy pulses that can non-thermally clear cells while minimizing damage to surrounding tissues. With its headquarters in Miami, Florida, the company is actively pursuing opportunities to leverage this technology not only for atrial fibrillation treatment but also in several other medically pertinent areas.
Frequently Asked Questions
What is Pulse Biosciences focusing on with their technology?
Pulse Biosciences is concentrating on advancing its nsPFA technology for better treatment outcomes in various medical fields, particularly in addressing atrial fibrillation and benign thyroid nodules.
What recent financial milestones did Pulse Biosciences achieve?
In Q3 2024, the company reported a GAAP net loss of ($12.7) million and an increase in cash reserves to $79.0 million, bolstered by a successful rights offering.
Who are the new appointments on Pulse Biosciences’ advisory board?
Dr. David Kenigsberg has been appointed as Chief Medical Officer for Electrophysiology, and Dr. Andrea Natale has joined the advisory board, broadening their expertise in this sector.
When does Pulse Biosciences plan to launch clinical trials?
They are targeting to commence pivotal clinical trials in mid-2025 for both their Percutaneous Electrode System and nano-PFA Cardiac Surgical System.
How does Pulse Biosciences measure its non-GAAP financial performance?
Pulse Biosciences uses non-GAAP measures to give a clearer picture of ongoing operations, excluding stock-based compensation, depreciation, and restructuring charges from its financial evaluations.
